Pfizer Submits sNDA to Expand Potential Market for Lasofoxifene

Ligand Pharmaceuticals has announced that Pfizer has confirmed a December 2004 FDA filing of a supplemental new drug application (NDA) for the use of lasofoxifene for the treatment of vaginal atrophy.

This follows an August 2004 NDA filing by Pfizer for use of lasofoxifene in the prevention of osteoporosis. Lasofoxifene is a selective estrogen receptor modulator and the first of Ligand's royalty-bearing products to get to the NDA submission stage. Lasofoxifene is also being developed by Pfizer for the treatment of osteoporosis.